Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on HilleVax, Inc (HLVX – Research Report), Lexicon ...

According to TipRanks.com, Archila is a 4-star analyst with an average return of 5.4% and a 45.0% success rate. Archila covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company ...

ARV-102 is Arvinas' investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Charles Schwab Investment Management Inc. lifted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN – Free Report) by 1.0% during the 4th quarter, according to its most recent disclosure with the ...

Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Arvinas in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the ...

Arvinas, Inc. (ARVN) has been beaten down lately with too much selling pressure. While the stock has lost 54.9% over the past four weeks, there is light at the end of the tunnel as it is now in ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) in adults with oestrogen receptor (ER)-positive, human epidermal growth ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the pump and dump ...